PharmaTher Plans to Develop Ketamine as Potential ALS Treatment
Under an agreement with the University of Kansas, PharmaTher has gained exclusive worldwide rights to develop and possibly commercialize ketamine as a therapy for amyotrophic lateral sclerosis (ALS). “We are pleased to have added the [ALS] program to our already impressive development pipeline…